Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Krystexxa | pegloticase | Horizon Therapeutics Public | N-125293 RX | 2010-09-14 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
krystexxa | Biologic Licensing Application | 2025-04-08 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
gout | EFO_0004274 | D006073 | M10 |
Expiration | Code | ||
---|---|---|---|
pegloticase, Krystexxa, Horizon Therapeutics Ireland DAC | |||
2117-09-14 | Orphan excl. |
Code | Description |
---|---|
J2507 | Injection, pegloticase, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gout | D006073 | EFO_0004274 | M10 | — | — | — | — | 1 | 1 |
Drug common name | Pegloticase |
INN | pegloticase |
Description | Tetramer alpha4 of des-(1-5)-[6-threonine,45-threonine,290-lysine,300-serine]uricase (EC 1.7.3.3, urate oxidase) from Sus scrofa (porcine), non acetylated, of which some of the lysine 6-amine residues are engaged in a carbamate linkage with a monomethylic ether of polyoxyethylene (macrogol) |
Classification | Enzyme |
Drug class | enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1237025 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB09208 |
UNII ID | R581OT55EA (ChemIDplus, GSRS) |